Key Takeaway: Contineum Therapeutics, a clinical-stage biopharmaceutical company, will present at the 2026 Leerink Partners Global Healthcare Conference on March 11th. The presentation will highlight their innovative therapies for neuroscience, inflammation, and immunology. The company is advancing several drug candidates in clinical trials, including PIPE-791 and PIPE-307.
Price reaction · baseline $14.1 (2026-03-03 close) · hit pre-market · 1 other CTNM headline(s) in the window, move may be shared
day 0 close · peak
+5.4%
day 1
-2.1%
day 3
-4%
Market Sentiment Analysis
POSITIVE FACTORS
Contineum Therapeutics is presenting at a notable healthcare conference.
The company is pioneering novel therapies for significant unmet medical needs.
Multiple drug candidates are currently in clinical trials.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+79%
120-day peak, hindsight
Typical move
6.4%
average across 3 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
PIPE-307 Dose A
Phase 2 · Relapsing Remitting Multiple Sclerosis
Full Press Release Details
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11th at 2:20 p.m. ET.
An audio webcast of the fireside chat can be accessed on theInvestorssection of Contineum’s website. A webcast replay will also be available.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visitwww.contineum-tx.com.
Frequently Asked Questions
When will Contineum present at the conference?
Contineum Therapeutics is scheduled to present on March 11th, 2026.
What is the focus of Contineum's therapies?
Contineum focuses on therapies for neuroscience, inflammation, and immunology.
Where can I access the presentation?
The presentation will be available via an audio webcast on Contineum's website.
What drug candidates is Contineum developing?
Contineum is developing PIPE-791 for pulmonary fibrosis and PIPE-307 for multiple sclerosis.